# Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer

> **NCT02282345** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 36 (actual)

## Conditions studied

- Breast Adenocarcinoma
- Deleterious BRCA1 Gene Mutation
- Deleterious BRCA2 Gene Mutation
- HER2/Neu Negative
- Invasive Breast Carcinoma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Talazoparib

## Key facts

- **NCT ID:** NCT02282345
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-16
- **Primary completion:** 2018-04-26
- **Final completion:** 2022-06-07
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2022-07-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02282345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02282345, "Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02282345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*